These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34277971)

  • 1. Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program.
    Wang KM; Li J; Bhalla V; Jardine MJ; Neal B; de Zeeuw D; Fulcher G; Perkovic V; Mahaffey KW; Chang TI
    Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00247. PubMed ID: 34277971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
    Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
    Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
    Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD
    ESC Heart Fail; 2021 Apr; 8(2):1482-1493. PubMed ID: 33595905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
    Sridhar VS; Neuen BL; Fletcher RA; Slee A; Ang FG; Rapattoni W; Arnott C; Cherney DZ; Perkovic V; Wheeler DC; Levin A
    Diabetes Obes Metab; 2023 Aug; 25(8):2331-2339. PubMed ID: 37184050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
    Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
    J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
    Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
    J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
    Yu J; Li J; Leaver PJ; Arnott C; Huffman MD; Udell JA; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Rosenthal N; Neal B; Figtree GA
    Cardiovasc Res; 2022 Mar; 118(4):1103-1114. PubMed ID: 33826709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
    Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
    Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
    Weir MR; Gogate J; Damaraju CV; Correa-Rotter R; Mahaffey KW
    Diabetes Obes Metab; 2022 Jan; 24(1):12-20. PubMed ID: 34463423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Li Q; Jardine M; Oh R; Heerspink HL; Perkovic V
    J Am Soc Nephrol; 2019 Nov; 30(11):2229-2242. PubMed ID: 31530577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
    Ohkuma T; Van Gaal L; Shaw W; Mahaffey KW; de Zeeuw D; Matthews DR; Perkovic V; Neal B
    Diabetes Obes Metab; 2020 Apr; 22(4):530-539. PubMed ID: 31729107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.
    Sen T; Li J; Neuen BL; Arnott C; Neal B; Perkovic V; Mahaffey KW; Shaw W; Canovatchel W; Hansen MK; Heerspink HJL
    J Am Heart Assoc; 2021 Dec; 10(23):e021661. PubMed ID: 34854308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.
    Gilbert RE; Mende C; Vijapurkar U; Sha S; Davies MJ; Desai M
    Diabetes Ther; 2017 Apr; 8(2):451-458. PubMed ID: 28197834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
    Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL
    Diabetologia; 2021 Oct; 64(10):2147-2158. PubMed ID: 34415356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
    Tang H; Zhang X; Zhang J; Li Y; Del Gobbo LC; Zhai S; Song Y
    Diabetologia; 2016 Dec; 59(12):2546-2551. PubMed ID: 27628105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.